XRCC3 Thr241Met Is Associated with Response to Platinum-Based Chemotherapy but Not Survival in Advanced Non-Small Cell Lung Cancer

摘要: Background A lot of studies have investigated the correlation between x-ray repair cross-complementing group 3 (XRCC3) Thr241Met polymorphism and clinical outcomes in non-small cell cancer (NSCLC), while conclusion is still conflicting. Materials Methods We conducted this meta-analysis to evaluate predictive value XRCC3 on response overall survival patients with NSCLC. Pooled odds ratios (ORs) hazard (HRs) corresponding 95% confidence intervals (95% CIs) were used estimate association strength. Results total 14 eligible 2828 identified according our inclusion criteria. Meta-analysis results showed that carriers variant 241Met allele significantly associated good response, compared those harboring wild 241Thr (Met vs. Thr, OR = 1.453, CI: 1.116–1.892, Pheterogeneity 0.968 ThrMet+MetMet ThrThr, 1.476, 1.087–2.004, 0.696). This significant was observed Caucasian population but not Asian population. On other hand, there no (ThrMet+MetMet HR 1.082, 0.929–1.261, 0.564), difference population. Conclusions These findings suggest a role platinum-based chemotherapy advanced Additionally, we first report highlights prognostic polymorphism.